Fig. 3From: Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMedian percentage change in MFSAF TSS from baseline to week 24. Includes patients from the intent-to-treat population with data at week 24. MFSAF TSS, Myelofibrosis Symptom Assessment Form Total Symptom Score. *The average daily dose during the 28 days before the spleen volume assessment (inclusive) at week 24Back to article page